尖峰集团：JFAN-1001甲磺酸盐胶囊药物临床试验获批

Core Viewpoint - The company has received approval from the National Medical Products Administration for its new anti-tumor drug, JFAN-1001 mesylate capsules, which targets a specific mutation in non-small cell lung cancer [1] Group 1: Company Developments - The wholly-owned subsidiary of the company,尖峰亦恩, has been granted the Clinical Trial Approval Notice for JFAN-1001 mesylate capsules [1] - JFAN-1001 mesylate capsules are classified as a Class 1 chemical drug and are developed for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-T790M secondary mutation [1]